MA37647A1 - Procédé de fabrication de composés de cyclopentapyrimidine hydroxylée et sels de ceux-ci - Google Patents

Procédé de fabrication de composés de cyclopentapyrimidine hydroxylée et sels de ceux-ci

Info

Publication number
MA37647A1
MA37647A1 MA37647A MA37647A MA37647A1 MA 37647 A1 MA37647 A1 MA 37647A1 MA 37647 A MA37647 A MA 37647A MA 37647 A MA37647 A MA 37647A MA 37647 A1 MA37647 A1 MA 37647A1
Authority
MA
Morocco
Prior art keywords
salts
compounds
producing hydroxylated
cyclopentapyrimidine compounds
hydroxylated cyclopentapyrimidine
Prior art date
Application number
MA37647A
Other languages
English (en)
Inventor
Srinivasan Babu
Francis Gosselin
Yingqing Ran
Travis Remarchuk
Scott J Savage
Jeffrey Stults
Herbert Yajima
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA37647A1 publication Critical patent/MA37647A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne de nouveaux procédés pour fabriquer et purifier des sels de composés de cyclopentapyrimidine hydroxylée, qui sont utiles en tant qu'inhibiteurs d'akt utilisés dans le traitement de maladies telles que le cancer, comprenant le sel monochlorhydrate de (s)-2-(4-chlorophényl)-1-(4-((5r,7r)-7-hydroxy-5-méthyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl)pipérazin-1-yl)-3-(isopropylamino)propan-1-one.
MA37647A 2012-05-17 2013-05-17 Procédé de fabrication de composés de cyclopentapyrimidine hydroxylée et sels de ceux-ci MA37647A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261648535P 2012-05-17 2012-05-17
PCT/US2013/041695 WO2013173784A1 (fr) 2012-05-17 2013-05-17 Procédé de fabrication de composés de cyclopentapyrimidine hydroxylée et sels de ceux-ci

Publications (1)

Publication Number Publication Date
MA37647A1 true MA37647A1 (fr) 2016-03-31

Family

ID=48534508

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37647A MA37647A1 (fr) 2012-05-17 2013-05-17 Procédé de fabrication de composés de cyclopentapyrimidine hydroxylée et sels de ceux-ci

Country Status (17)

Country Link
US (1) US9315471B2 (fr)
EP (1) EP2850200A1 (fr)
JP (1) JP6355625B2 (fr)
KR (1) KR102123131B1 (fr)
CN (1) CN104471070B (fr)
AU (1) AU2013262521B2 (fr)
BR (1) BR112014028573B1 (fr)
CA (1) CA2873661C (fr)
IL (1) IL235699B (fr)
MA (1) MA37647A1 (fr)
MX (1) MX354373B (fr)
MY (1) MY169029A (fr)
NZ (1) NZ702950A (fr)
RU (1) RU2642311C2 (fr)
SG (1) SG11201407591PA (fr)
WO (1) WO2013173784A1 (fr)
ZA (1) ZA201409226B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102678074B1 (ko) 2012-05-17 2024-06-26 제넨테크, 인크. 무정형 형태의 akt 저해성 피리미디닐 - 사이클로펜탄 화합물, 조성물 및 이들의 방법
SI2861583T1 (sl) 2012-05-17 2016-10-28 Array Biopharma, Inc. Postopek za izdelavo hidroksiliranih ciklopentilpirimidinskih spojin
CA2873654C (fr) 2012-05-17 2021-06-22 Array Biopharma Inc. Procede de fabrication de composes de cyclopentylpyrimidine hydroxylee
PL2850054T3 (pl) 2012-05-17 2018-08-31 Genentech, Inc. Sposób wytwarzania związków aminokwasowych
EP3068770B1 (fr) 2013-11-15 2019-10-23 F.Hoffmann-La Roche Ag Procédé de préparation de composés de pyrimidinylcyclopentane
MX380718B (es) * 2014-09-26 2025-03-12 Hoffmann La Roche Procesos para preparar compuestos de (ciclopentil[d]pirimidin-4-il)piperazina
IL264593B (en) 2016-08-10 2022-07-01 Hoffmann La Roche Medicinal preparations containing akt protein kinase inhibitors
US20220025424A1 (en) * 2016-08-16 2022-01-27 Imago Biosciences, Inc. Compositions and methods for producing stereoisomerically pure aminocyclopropanes
WO2019122421A1 (fr) * 2017-12-22 2019-06-27 Astrazeneca Ab Réduction stéréosélective de cétone à l'aide d'une enzyme cétoréductase
CA3186562A1 (fr) * 2020-07-22 2022-01-27 Jian Wu Sel et forme cristalline de derive de dihydropyrido[2,3-d]pyrimidine
CN115916350B (zh) * 2020-07-22 2024-11-05 南京正大天晴制药有限公司 Akt抑制剂的单位剂量组合物
WO2023043869A1 (fr) 2021-09-15 2023-03-23 Teva Pharmaceuticals International Gmbh Formes à l'état solide de citrate d'ipatasertib

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9408197A (pt) 1993-12-12 1997-08-26 Agrogene Ltd Método para proteger plantas contra doenças fúngicas
AU724216B2 (en) 1997-04-07 2000-09-14 Merck & Co., Inc. A method of treating cancer
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
AU1302999A (en) * 1997-11-04 1999-05-24 Eli Lilly And Company Ketoreductase gene and protein from yeast
EP0982300A3 (fr) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines comme antagonistes du recepteur histamine H3 et leur application thérapeutique
CA2363169A1 (fr) 1999-03-03 2000-09-08 Merck & Co., Inc. Inhibiteurs de la prenyle-proteine transferase
WO2001022963A1 (fr) 1999-09-27 2001-04-05 Merck & Co., Inc. Procede de prevention de l'osteoporose
DE10119274A1 (de) * 2001-04-20 2002-10-31 Juelich Enzyme Products Gmbh Enzymatisches Verfahren zur enantioselektiven Reduktion von Ketoverbindungen
CA2526506A1 (fr) 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibiteurs du papillomavirus
KR100959771B1 (ko) * 2005-06-10 2010-05-28 머크 샤프 앤드 돔 코포레이션 Ａｋｔ 활성의 억제제
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
EP2198018B1 (fr) * 2007-09-13 2013-11-20 Codexis, Inc. Polypeptides de cétoréductase pour la réduction d'acétophénones
WO2009047255A1 (fr) 2007-10-09 2009-04-16 Ucb Pharma, S.A. Composés hétérobicycliques utiles comme antagonistes du récepteur h4 de l'histamine
AU2009204019B2 (en) * 2008-01-09 2014-02-20 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
RU2541571C2 (ru) 2009-04-15 2015-02-20 Эббви Инк. Противовирусные соединения
US8436002B2 (en) 2009-10-23 2013-05-07 Eli Lilly And Company AKT inhibitors
EP2592933B1 (fr) 2010-07-16 2017-04-05 Anderson Gaweco Inhibiteurs mif et leurs utilisations
WO2012177925A1 (fr) 2011-06-21 2012-12-27 The Board Institute, Inc. Inhibiteurs akt pour le traitement d'un cancer exprimant un gène de fusion magi3 - akt3
PL2850054T3 (pl) 2012-05-17 2018-08-31 Genentech, Inc. Sposób wytwarzania związków aminokwasowych
CA2873654C (fr) 2012-05-17 2021-06-22 Array Biopharma Inc. Procede de fabrication de composes de cyclopentylpyrimidine hydroxylee
SI2861583T1 (sl) 2012-05-17 2016-10-28 Array Biopharma, Inc. Postopek za izdelavo hidroksiliranih ciklopentilpirimidinskih spojin
CA2889855A1 (fr) 2012-11-01 2014-05-08 Robert S. Katz Methodes de traitement de la fibromyalgie
JP2016513112A (ja) 2013-02-18 2016-05-12 ザ スクリプス リサーチ インスティテュート 治療的潜在能力を有するバソプレッシン受容体のモジュレーター
CN105473141A (zh) 2013-03-15 2016-04-06 实发生物医学公司 治疗和/或预防心血管疾病的抗pcsk9化合物和方法

Also Published As

Publication number Publication date
BR112014028573B1 (pt) 2021-11-16
US20150099880A1 (en) 2015-04-09
IL235699A0 (en) 2015-01-29
EP2850200A1 (fr) 2015-03-25
RU2642311C2 (ru) 2018-01-24
KR20150018579A (ko) 2015-02-23
WO2013173784A1 (fr) 2013-11-21
NZ702950A (en) 2016-09-30
CN104471070A (zh) 2015-03-25
CA2873661A1 (fr) 2013-11-21
AU2013262521B2 (en) 2017-03-02
MX2014013855A (es) 2016-03-21
JP6355625B2 (ja) 2018-07-11
BR112014028573A2 (pt) 2018-04-24
HK1208500A1 (en) 2016-03-04
ZA201409226B (en) 2017-09-27
KR102123131B1 (ko) 2020-06-15
MY169029A (en) 2019-02-04
CA2873661C (fr) 2020-07-21
CN104471070B (zh) 2018-09-25
US9315471B2 (en) 2016-04-19
AU2013262521A1 (en) 2015-01-22
SG11201407591PA (en) 2015-01-29
RU2014151014A (ru) 2016-07-10
IL235699B (en) 2018-12-31
JP2015518715A (ja) 2015-07-06
MX354373B (es) 2018-02-28

Similar Documents

Publication Publication Date Title
MA37647A1 (fr) Procédé de fabrication de composés de cyclopentapyrimidine hydroxylée et sels de ceux-ci
MA37649B1 (fr) Procédé de fabrication de composés cyclopentylpyrimidines hydroxylées
WO2010147898A3 (fr) Inhibiteurs à petite molécule de la tyrosine kinase de la rate (syk)
JOP20190151B1 (ar) مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان
MA41134B1 (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
MX368042B (es) COMPUESTOS ÚTILES COMO INHIBIDORES DE CINASA RELACIONADA CON ATAXIA TELANGIECTASIA MUTADA Y Rad3 (ATR).
MX358818B (es) Compuestos utiles como inhibidores de cinasa ataxia telangiectasia mutada y rad3 relacionados (atr) y terapias de combinacion de estos.
MX2016007371A (es) Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados.
IN2014KN00943A (fr)
UA111854C2 (uk) Способи і проміжні сполуки для отримання інгібіторів jak
NO20083918L (no) Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser
EA201270480A1 (ru) Новые соединения
EA201391528A1 (ru) Ингибиторы тирозинкиназы
MA37751A1 (fr) Procédé de préparation de composés d'acides aminés
MX2018002885A (es) Sales de inhibidor de pim cinasa.
MA39170A1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
EA201692255A1 (ru) Улучшенные формы селективного ингибитора pi3k-дельта для применения в фармацевтических препаратах
JP2011509306A5 (fr)
MX2010006331A (es) Hidantoinas sustituidas como inhibidores de cinasa mek.
EA201170736A1 (ru) Синтез и новые солевые формы (r)-3-((e)-2-(пирролидин-3-ил)винил)-5-(тетрагидропиран-4-илокси) пиридина
AR102088A1 (es) Procesos para preparar compuestos de (ciclopentil[d]pirimidin-4-il)piperazina
MA39020A1 (fr) Sels de l'acide 1 -(3-méthyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluorométhyl)-2,3-dihydro-lh-indén-1 -yl]-1,2,3,4-tétrahydropyrimidine-5-carboxylique
MX384986B (es) Sal y formas polimorficas de (3r,4s)-l-((4-amino-5h-pirrolo[3,2-d]pirimidin-7-il)metil)-4(metiltiometil)pirodin-3-ol(mtdia).
MA44503B1 (fr) Composés de pyrrolotriazine en tant qu'inhibiteurs de tam
EA201990404A1 (ru) Улучшенные формы селективного ингибитора pi3k-дельта для применения в фармацевтических препаратах